What does PHARMAVOX do?

PHARMAVOX is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”. Also registered: property company, consultancy, holding company. Private Limited, started on 7 December 2011, 1 establishment.

What is the address of PHARMAVOX?

The registered office of PHARMAVOX is located at Terhulpsesteenweg 178 box 5, 1170 Watermaal-Bosvoorde.

Is PHARMAVOX still active?

Yes. According to the CBE (31 October 2026) PHARMAVOX is active, legal situation “Normale toestand”, started on 7 December 2011.

Is PHARMAVOX registered on Peppol?

Yes, PHARMAVOX is registered on the Peppol network with ID 0208:0841606444.

What is the enterprise number of PHARMAVOX?

The enterprise number of PHARMAVOX is BE0841606444.

When was PHARMAVOX founded?

PHARMAVOX was founded on 7 December 2011.

Who are the directors of PHARMAVOX?

According to the 2026 annual accounts, the directors of PHARMAVOX are: BILIVIT SRL, Camille BOURELY, Gabrielle BOURELY, Michel BOURELY, BELGABY SRL.

Is PHARMAVOX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 December 2011; 5 annual accounts filed, latest fiscal year 2026; 5 directors known from the annual account.

How much profit did PHARMAVOX make in 2026?

PHARMAVOX recorded a loss after taxes of € 475,741 in financial year 2026.

What is the revenue of PHARMAVOX?

As a small company, PHARMAVOX is not required to publish revenue in its annual accounts. In financial year 2026, its added value was € 380,545.

How many employees does PHARMAVOX have?

According to the 2026 annual accounts, PHARMAVOX has 0 full-time equivalents (FTE).

PHARMAVOX (Private Limited) - Watermaal-Bosvoorde

Dossier PHARMAVOX, printed on 31 October 2026 from databakkes.be/en/0841606444/pharmavox. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2025 and 2026.
Tight liquidity NBB

Cash and receivables cover 5 % of short-term debt in 2026; threshold 65 %.
Busy address KBO

43 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2026

PHARMAVOX from Watermaal-Bosvoorde, company number BE0841606444, closed financial year 2026 with a result of € -475,741 after tax. For that financial year PHARMAVOX recorded a gross margin of € 380,545 and equity of € 6.4 million. Compared with financial year 2025, the result moved from € -323,574 to € -475,741. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 16, 2026.

What it is worth Healthy

€ 6.4 million

▼ 7% vs 2025

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -475,741

▼ 47 % more loss than in 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 72,230

▼ 28% vs 2025

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -2.8 million.

People and assets in 2026

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 1,591

▼ 53% vs 2025

Book value of vehicles, furniture and equipment.

Debts at end 2026

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2.7 million

▼ 7% vs 2025

€ 217,200 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 15,284

▲ € 12,246 vs 2025

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 17

▼ 96% vs 2025

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	2026	Change 2025 → 2026
Gross margin	€ 343,727 Gross margin 2023: € 343,727 First fiscal year in the series	€ 429,765 Gross margin 2024: € 429,765 ▲ 25% vs 2023 (€ 343,727) Favourable step	€ 353,155 Gross margin 2025: € 353,155 ▼ 18% vs 2024 (€ 429,765) Unfavourable step	€ 380,545 Gross margin 2026: € 380,545 ▲ 8% vs 2025 (€ 353,155) Favourable step	▲ 8%
Profit after taxes	€ -331,487 Profit after taxes 2023: € -331,487 First fiscal year in the series	€ -220,359 Profit after taxes 2024: € -220,359 ▲ € 111,128 vs 2023 (€ -331,487) Favourable step	€ -323,574 Profit after taxes 2025: € -323,574 ▼ € 103,215 vs 2024 (€ -220,359) Unfavourable step	€ -475,741 Profit after taxes 2026: € -475,741 ▼ € 152,167 vs 2025 (€ -323,574) Unfavourable step	▼ € 152,167
Equity	€ 7,424,645 Equity 2023: € 7,424,645 First fiscal year in the series	€ 7,204,285 Equity 2024: € 7,204,285 ▼ 3% vs 2023 (€ 7,424,645) Unfavourable step	€ 6,880,711 Equity 2025: € 6,880,711 ▼ 4% vs 2024 (€ 7,204,285) Unfavourable step	€ 6,404,971 Equity 2026: € 6,404,971 ▼ 7% vs 2025 (€ 6,880,711) Unfavourable step	▼ 7%
Total debts	€ 5,685,578 Total debts 2023: € 5,685,578 First fiscal year in the series	€ 5,529,805 Total debts 2024: € 5,529,805 ▼ 3% vs 2023 (€ 5,685,578) Favourable step	€ 4,379,441 Total debts 2025: € 4,379,441 ▼ 21% vs 2024 (€ 5,529,805) Favourable step	€ 4,136,316 Total debts 2026: € 4,136,316 ▼ 6% vs 2025 (€ 4,379,441) Favourable step	▼ 6%
Cash	€ 543,181 Cash 2023: € 543,181 First fiscal year in the series	€ 510,510 Cash 2024: € 510,510 ▼ 6% vs 2023 (€ 543,181) Unfavourable step	€ 99,768 Cash 2025: € 99,768 ▼ 80% vs 2024 (€ 510,510) Unfavourable step	€ 72,230 Cash 2026: € 72,230 ▼ 28% vs 2025 (€ 99,768) Unfavourable step	▼ 28%
Land & buildings	€ 11,274,113 Land & buildings 2023: € 11,274,113 First fiscal year in the series	€ 10,836,892 Land & buildings 2024: € 10,836,892 ▼ 4% vs 2023 (€ 11,274,113) Unchanged	€ 10,402,115 Land & buildings 2025: € 10,402,115 ▼ 4% vs 2024 (€ 10,836,892) Unchanged	€ 9,966,091 Land & buildings 2026: € 9,966,091 ▼ 4% vs 2025 (€ 10,402,115) Unchanged	▼ 4%
Retained profit	€ -1,785,355 Retained profit 2023: € -1,785,355 First fiscal year in the series	€ -2,005,715 Retained profit 2024: € -2,005,715 ▼ € 220,359 vs 2023 (€ -1,785,355) Unfavourable step	€ -2,329,289 Retained profit 2025: € -2,329,289 ▼ € 323,574 vs 2024 (€ -2,005,715) Unfavourable step	€ -2,805,029 Retained profit 2026: € -2,805,029 ▼ € 475,741 vs 2025 (€ -2,329,289) Unfavourable step	▼ € 475,741
Bank debt	€ 3,348,400 Bank debt 2023: € 3,348,400 First fiscal year in the series	€ 3,131,200 Bank debt 2024: € 3,131,200 ▼ 6% vs 2023 (€ 3,348,400) Favourable step	€ 2,914,000 Bank debt 2025: € 2,914,000 ▼ 7% vs 2024 (€ 3,131,200) Favourable step	€ 2,696,812 Bank debt 2026: € 2,696,812 ▼ 7% vs 2025 (€ 2,914,000) Favourable step	▼ 7%
Balance sheet total	€ 13,110,222 Balance sheet total 2023: € 13,110,222 First fiscal year in the series	€ 12,734,090 Balance sheet total 2024: € 12,734,090 ▼ 3% vs 2023 (€ 13,110,222) Unchanged	€ 11,260,152 Balance sheet total 2025: € 11,260,152 ▼ 12% vs 2024 (€ 12,734,090) Unchanged	€ 10,541,286 Balance sheet total 2026: € 10,541,286 ▼ 6% vs 2025 (€ 11,260,152) Unchanged	▼ 6%

Key figures of PHARMAVOX, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.

What happened to PHARMAVOX?

What happened at PHARMAVOX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 16, 2026 New annual accounts for financial year 2026: loss of € 475,741. Source: NBB ↗
2019 BILIVIT SRL became a director. NBB
2019 Camille BOURELY became a director. NBB
2019 Gabrielle BOURELY became a director. NBB
2019 Michel BOURELY became a director. NBB
2019 BELGABY SRL became a director. NBB
Dec 7, 2011 New establishment in Watermaal-Bosvoorde. KBO
Dec 7, 2011 Start of the company according to the CBE. KBO

In short

From € 331,487 loss in 2023 to € 475,741 loss in 2026.

Original PDFs at the National Bank ↗

Management

BILIVIT SRL Camille BOURELY Gabrielle BOURELY Michel BOURELY +1

PHARMAVOX

BELGABY

Behind PHARMAVOX are BILIVIT SRL, Camille BOURELY, Gabrielle BOURELY, Michel BOURELY and BELGABY SRL. Gabrielle BOURELY is also behind BELGABY.

Directors

According to the 2026 annual accounts

BILIVIT SRL

Director · represented by BOURELY Camille

since 2019

Camille BOURELY

Director

since 2019

Gabrielle BOURELY

Director

Also active at: BELGABY

since 2019

Michel BOURELY

Director

since 2019

BELGABY SRL

Director · represented by BOURELY Gabrielle

since 2019

Establishments

Establishment units

Physical locations of this company

Registered office

Terhulpsesteenweg 178 box 5

1170 Watermaal-Bosvoorde

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 43 companies are registered at this address.

All companies at this address →

Anc. Ets. F. Verdeyen

TAX CONSULT

€ 651,315 gross margin · 2025

CMS DeBacker

€ 27.5 million revenue · 2025

MNG-MANGO BELGIQUE

€ 35 million revenue · 2025

BRUNO DUQUESNE

€ 182,007 gross margin · 2025

+38 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0841.606.444

VAT number

BE 0841.606.444

Registered office

Terhulpsesteenweg 178 bus 5, 1170 Watermaal-Bosvoorde

Names & denominations

PHARMAVOX

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

7 December 2011

Peppol

Active · Active since 17 Jul 2025

Activities · NACE

Overige zakelijke dienstverlening, neg

Activiteiten van holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMAVOX

Warning lights

Financials

What happened to PHARMAVOX?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions